A Bentley biotech company led by Graham Melrose is planning a $5 million initial public offering, after six years of research on the development of synthetic antibiotics.
A Bentley biotech company led by Graham Melrose is planning a $5 million initial public offering, after six years of research on the development of synthetic antibiotics.